Kyverna Therapeutics (KYTX) Competitors $3.85 -0.48 (-11.09%) Closing price 07/29/2025 04:00 PM EasternExtended Trading$3.88 +0.03 (+0.91%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. MNMD, ZVRA, DNTH, DAWN, ATAI, AUTL, XNCR, ABVX, TLRY, and MRVIShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Mind Medicine (MindMed) (MNMD), Zevra Therapeutics (ZVRA), Dianthus Therapeutics (DNTH), Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), Autolus Therapeutics (AUTL), Xencor (XNCR), Abivax (ABVX), Tilray Brands (TLRY), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Its Competitors Mind Medicine (MindMed) Zevra Therapeutics Dianthus Therapeutics Day One Biopharmaceuticals atai Life Sciences Autolus Therapeutics Xencor Abivax Tilray Brands Maravai LifeSciences Kyverna Therapeutics (NASDAQ:KYTX) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do insiders & institutionals hold more shares of KYTX or MNMD? 18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 2.3% of Mind Medicine (MindMed) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is KYTX or MNMD more profitable? Mind Medicine (MindMed)'s return on equity of -40.33% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.66% -45.92% Mind Medicine (MindMed) N/A -40.33%-32.13% Do analysts recommend KYTX or MNMD? Kyverna Therapeutics presently has a consensus price target of $18.50, suggesting a potential upside of 380.52%. Mind Medicine (MindMed) has a consensus price target of $24.00, suggesting a potential upside of 162.58%. Given Kyverna Therapeutics' higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Mind Medicine (MindMed).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media refer more to KYTX or MNMD? In the previous week, Mind Medicine (MindMed) had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 6 mentions for Mind Medicine (MindMed) and 3 mentions for Kyverna Therapeutics. Mind Medicine (MindMed)'s average media sentiment score of 0.99 beat Kyverna Therapeutics' score of 0.88 indicating that Mind Medicine (MindMed) is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mind Medicine (MindMed) 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, KYTX or MNMD? Kyverna Therapeutics has a beta of 2.95, meaning that its share price is 195% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.45, meaning that its share price is 145% more volatile than the S&P 500. Which has higher valuation & earnings, KYTX or MNMD? Mind Medicine (MindMed) has lower revenue, but higher earnings than Kyverna Therapeutics. Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M23.67-$127.48M-$3.38-1.14Mind Medicine (MindMed)N/AN/A-$108.68M-$1.29-7.09 SummaryMind Medicine (MindMed) beats Kyverna Therapeutics on 11 of the 15 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$187.14M$3.02B$5.70B$9.55BDividend YieldN/A2.39%4.71%4.03%P/E Ratio-1.1421.1428.2019.95Price / Sales23.67206.95390.5767.75Price / CashN/A42.5736.3258.72Price / Book0.628.138.275.77Net Income-$127.48M-$55.06M$3.25B$259.21M7 Day Performance-11.09%-3.70%-2.00%-2.40%1 Month Performance25.41%14.45%8.68%9.41%1 Year Performance-56.00%4.20%34.66%16.67% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics2.1663 of 5 stars$3.85-11.1%$18.50+380.5%-59.3%$187.14M$7.03M-1.1496News CoverageMNMDMind Medicine (MindMed)2.1718 of 5 stars$9.95+12.0%$25.50+156.3%+0.4%$670.91MN/A-7.7140High Trading VolumeZVRAZevra Therapeutics2.8976 of 5 stars$11.73-2.8%$23.71+102.2%+85.1%$659.98M$23.61M-6.1720Analyst RevisionDNTHDianthus Therapeutics1.273 of 5 stars$20.74+1.7%$53.00+155.5%-25.9%$656.06M$6.24M-7.2080Upcoming EarningsDAWNDay One Biopharmaceuticals2.9265 of 5 stars$6.40flat$29.00+353.1%-54.5%$648.72M$131.16M-9.0160Positive NewsUpcoming EarningsATAIatai Life Sciences3.742 of 5 stars$3.53+9.3%$9.00+155.0%+109.5%$647.09M$310K-3.8880Analyst ForecastGap UpHigh Trading VolumeAUTLAutolus Therapeutics2.4451 of 5 stars$2.43+0.8%$9.32+283.5%-47.7%$641.40M$10.12M-2.76330Gap UpXNCRXencor4.4327 of 5 stars$9.10+1.4%$28.00+207.7%-58.0%$638.40M$110.49M-2.97280Upcoming EarningsABVXAbivax3.2345 of 5 stars$10.14+1.9%$31.00+205.7%+491.0%$631.55MN/A0.0061Analyst ForecastHigh Trading VolumeTLRYTilray Brands1.7456 of 5 stars$0.67+8.4%$1.92+184.6%-68.5%$625.34M$788.94M-0.642,650Trending NewsEarnings ReportAnalyst ForecastGap DownMRVIMaravai LifeSciences3.4785 of 5 stars$2.38-2.1%$6.64+178.9%-72.8%$618.82M$259.18M-2.09610News CoverageUpcoming Earnings Related Companies and Tools Related Companies MNMD Alternatives ZVRA Alternatives DNTH Alternatives DAWN Alternatives ATAI Alternatives AUTL Alternatives XNCR Alternatives ABVX Alternatives TLRY Alternatives MRVI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredSmall Cap- AI Hospitals = Big OpportunityA tiny NASDAQ firm just launched a generative AI platform aimed at disrupting a $2 trillion healthcare market....Smallcaps Daily | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
